IMRT

Summarising • Models to convert dose distributions into clinical outcome exist and have been verified in certain cases (e.g. rectum, lung, liver)

• Care must taken if extending the application outside the range where the parameter-fitting has been done

• If possible, take into account the weight of the clinical variables (including the genetic ones) in the models

• (Iso-NTCP treatment plan individualisation could be a strategy to improve clinical outcome

• Inclusion of deformation during the treatment (doses really absorbed in the voxels, elastic match, shrinkage effects etc))